Urea

Generic Name: Urea

Brand Names: Cem-urea, Umecta, Utopic

Drug Type: Small Molecule

Chemical Formula: CH_₄N_₂O

CAS Number: 57-13-6

Unique Ingredient Identifier: 8W8T17847W

Background: A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids.

Indication: Urea is used topically for debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails.

Associated Conditions: Allergic Skin Reaction, Atopic Dermatitis, Contact Dermatitis, Dermatitis, Dry Eyes, Dry Skin, Dry Skin; Eczema, Eczema, Dyshidrotic, Eye pruritus, Helicobacter Pylori Infection, Insect Bites, Lichen Planus (LP), Neurodermatitis, Nummular Dermatitis, Psoriasis, Seborrheic Dermatitis, Sunburn, Anal eczema, Calluses

Associated Therapies: Moisturizing

Clinical Trials

The Efficacy and Safety of Liangxue Ointment in the Treatment of Hand-foot Syndrome Caused by VEGFR-TKI Drugs

Not Applicable

Recruiting

Conditions: Hand-Foot Syndrome

Interventions: Drug: Liangxue ointment（Traditional Chinese Ointment）
Drug: Urea cream

First Posted Date: 2024-09-04

Last Posted Date: 2024-09-04

Lead Sponsor: Peking University Cancer Hospital & Institute

Target Recruit Count: 220

Registration Number: NCT06583369

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

Adding Urea to the Final Dialysis Fluid

Phase 1

Not yet recruiting

Conditions: Hyperkalemia
Dysequilibrium Syndrome
ESRD
Metabolic Acidosis

Interventions: Drug: Urea in the dialysate

First Posted Date: 2024-04-15

Last Posted Date: 2024-04-15

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 20

Registration Number: NCT06366230

Locations: 🇺🇸
Zuckerberg San Francisco General Hospital, San Francisco, California, United States

Efficacy of Combination of Hdroxyurea and Thalidomide Over Either Hydroxyurea or Thalidomide Alone in the Treatment of Transfusion Dependent Thalassemia in Children: A Quasi-Randomised Clinical Trial

Phase 4

Recruiting

Conditions: Transfusion-dependent Thalassemia

Interventions: Drug: Hydroxy Urea
Drug: Combinations
Drug: Thalidomide

First Posted Date: 2024-03-08

Last Posted Date: 2024-03-08

Lead Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Target Recruit Count: 90

Registration Number: NCT06299670

Locations: 🇧🇩
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Urea Cream Prevention for Capecitabine Associated Hand Foot Syndrome

Phase 2

Conditions: Hand-Foot Syndrome

Interventions: Drug: Urea cream

First Posted Date: 2022-04-27

Last Posted Date: 2022-04-27

Lead Sponsor: Mahidol University

Target Recruit Count: 214

Registration Number: NCT05348278

Locations: 🇹🇭
Division of medical oncology, department of medicine Siriraj Hospital, Bangkok, Thailand

Urea for Chronic Hyponatremia

Phase 2

Terminated

Conditions: Hyponatremia
Inappropriate ADH Syndrome

Interventions: Drug: Urea

First Posted Date: 2020-10-19

Last Posted Date: 2024-05-20

Lead Sponsor: Helbert Rondon Berrios, MD, MS

Target Recruit Count: 2

Registration Number: NCT04588207

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage

Not Applicable

Active, not recruiting

Conditions: Hyponatremia
Subarachnoid Hemorrhage
SIADH

Interventions: Other: PLACEBO
Drug: Urea

First Posted Date: 2020-09-17

Last Posted Date: 2025-04-16

Lead Sponsor: University Hospital, Grenoble

Target Recruit Count: 52

Registration Number: NCT04552873

Locations: 🇫🇷
University Hospital Grenoble, Grenoble, France

Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia

Phase 2

Completed

Conditions: Vaso-occlusive Crisis
Sickle Cell Disease
Sickle Cell Anemia in Children

Interventions: Drug: Omega 3
Drug: Statins (Cardiovascular Agents)
Drug: Vit D
Drug: Zinc sulfate
Drug: Hydroxy Urea
Drug: Folic Acid Supplementation
Drug: Morphine Sulfate
Procedure: blood transfusion session

First Posted Date: 2020-03-10

Last Posted Date: 2021-01-27

Lead Sponsor: Beni-Suef University

Target Recruit Count: 350

Registration Number: NCT04301336

Locations: 🇪🇬
Faculty of Pharmacy, Beni-Suef university, Banī Suwayf, Egypt
🇪🇬
Health insurance hospital, Banī Suwayf, Egypt
🇪🇬
Faculty of medicine, Beni-suef univeristy - Beni-Seuf university hospital, Banī Suwayf, Egypt

and more 1 locations